|1.||Bergamini, Ettore: 2 articles (04/2011 - 07/2004)|
|2.||Jensen, Michael D: 2 articles (03/2007 - 06/2006)|
|3.||Dieguez, Carlos: 2 articles (08/2003 - 02/2003)|
|4.||Cordido, Fernando: 2 articles (08/2003 - 02/2003)|
|5.||Casanueva, Felipe F: 2 articles (08/2003 - 02/2003)|
|6.||Leoni, F: 2 articles (03/2002 - 11/2001)|
|7.||Ciampelli, M: 2 articles (03/2002 - 11/2001)|
|8.||Lanzone, A: 2 articles (03/2002 - 11/2001)|
|9.||Marculescu, Rodrig: 1 article (04/2015)|
|10.||Luger, Anton: 1 article (04/2015)|
10/01/1988 - "In a study to check whether the drug improved hemo-rheological parameters, 21 patients (17 M, 4 F) with asymptomatic hypertriglyceridemia were treated with acipimox (250 b.i.d.) for 30 days. "
11/01/2006 - "A 3-month, randomized, double-blind, controlled trial of acipimox (250 mg thrice daily) vs. placebo was conducted in 23 HIV-infected men and women with hypertriglyceridemia (>150 mg/dl), abnormal fat distribution, and no current lipid-lowering therapy. "
02/01/1985 - "Accordingly, a dosage schedule of 50 mg or 100 mg of acipimox after each dialysis session was selected for a second, 4-week study in 14 uremic patients with hypertriglyceridemia. "
01/01/1991 - "Increased affinity of LDL for their receptors after acipimox treatment in hypertriglyceridemia."
05/01/1997 - "In the present study, we evaluated the effect of acipimox in Chinese NIDDM patients with hypertriglyceridemia. "
|2.||Type 2 Diabetes Mellitus (MODY)
03/01/1998 - "Sixty NIDDM patients (43 males and 17 females) took part in a randomized controlled trial of acipimox or placebo for 12 weeks. "
03/01/1994 - "This suggests that caution should be employed concerning long term use of acipimox as a hypoglycemic agent in NIDDM patients."
11/01/1992 - "Metabolic effects of suppression of nonesterified fatty acid levels with acipimox in obese NIDDM subjects."
10/01/1992 - "Twelve NIDDM patients were randomized to treatment with either placebo or Acipimox in pharmacological doses (250 mg x 3) for three months. "
05/01/1992 - "We have therefore measured the acute changes that occur 120-150 min after administration of 500 mg of the antilipolytic agent acipimox in eight non-obese male patients with non-insulin-dependent diabetes mellitus. "
01/01/1985 - "[Treatment of primary hyperlipidemia with 5-methylpyrazinecarboxylic acid (acipimox)]."
12/04/1982 - "[Acipimox treatment of hyperlipidemia type II]."
12/01/1980 - "In consideration of the very good subjective tolerability of acipimox at all doses tested, this drug may be suitable for control of lipolysis in hyperlipidemias."
09/01/1993 - "To study the tolerability and efficacy of acipimox on hyperlipidemia and diabetes compensation in patients with NIDDM under conditions of a routine clinical practice. "
04/16/2000 - "Acipimox can therefore be used as a second-line drug, mainly in those with combined hyperlipidemia and hypertriglyceridemia."
12/01/2009 - "The study provided detailed information to support and guide the formulation strategy for a MR form of acipimox, which may improve the treatment of adult patients with type II diabetes and dyslipidemia."
09/01/1993 - "Acipimox seems to be a useful agent for treatment of diabetic dyslipidemia and does not deteriorate glycemic control."
12/01/1995 - "This result suggests Olbetam can improve dyslipidemia in NIDDM and was well tolerated by all patients."
12/01/2009 - "Acipimox is an analog of nicotinic acid and is indicated for the treatment of dyslipidemia. "
05/01/1997 - "Acipimox, being widely prescribed for treating hypertriglyceridemia, is also used in NIDDM patients for their dyslipidemia. "
08/01/1994 - "[Assessment of hypolipemic action of the preparation olbetam in people with primary hypercholesterolemia]."
01/01/1999 - "An 8-week, randomized, double-blind study comparing the efficacy and tolerability of policosanol and acipimox was conducted in patients with type II hypercholesterolemia. "
01/01/1999 - "A comparative study of policosanol Versus acipimox in patients with type II hypercholesterolemia."
02/01/1997 - "Our findings suggest that, although both drugs at the standard dose employed in the study were effective in improving the lipid profile; in the treatment of combined hyperlipidemia acipimox might be preferable in the presence of more pronounced hypertriglyceridemia with low levels of HDL-C, whereas pravastatin might be more useful when hypercholesterolemia is predominant."
04/15/2012 - "Acipimox (100 mg kg(-1) day(-1), 4 weeks) reduced serum insulin, NEFA, and triglyceride concentrations without affecting glucose tolerance and hypercholesterolemia. "
|4.||Nonesterified Fatty Acids (NEFA)
|9.||Niacin (Nicotinic Acid)
|10.||Growth Hormone (Somatotropin)
|2.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)